ABOUT US

Luye has established research and development (R&D) centers in the United States, Europe, and China.

Founded in 1994, Luye Life Sciences Group operates across four key sectors: pharmaceuticals, vaccines, healthcare services, and diagnostics, spanning over 80 countries and regions. With nearly 10,000 employees worldwide, the Group focuses on central nervous system (CNS) disorders, oncology, cardiovascular diseases, and viral and pathogenic infections.

Since 2021, Luye has received approval for 16 innovative products. Among these, ERZOFRI® (paliperidone palmitate) received FDA approval, and its launch in 2025 served as a foundation for the establishment of Luye Pharma USA.

ERZOFRI® carries a BOXED WARNING:

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ERZOFRI® is not approved for use in patients with dementia-related psychosis.